Market Overview

Amicus Therapeutics Up 25% Following FDA Decision To Allow New Application For Migalastat


Amicus Therapeutics, Inc. (NASDAQ: FOLD) shares are trading higher by $2.61 (25.5 percent) at $12.87 in Tuesday's session.

Before the open, the FDA confirmed that the company may submit a New Drug Application for Migalastat for Fabry Disease.

After a much higher open, Amicus had a brief decline to $12.30 before roaring back to make a new high for the day at $13.28. That marks the highest level for the stock since October 2015, when it peaked at $13.78.

Since making that intraday high, it has been struggling to remain in the $13.00 handle.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (FOLD)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Russian-Interference Saga Continues As Trump Jr. Tweets Email Exchanges

12 Biggest Mid-Day Gainers For Tuesday